药物对比
Canagliflozin vs Linagliptin
Canagliflozin（Invokana）是用于2型糖尿病的SGLT2抑制剂；Linagliptin（Tradjenta）是DPP-4抑制剂。比较用途、机制与安全性。
此页面暂无可用的对比维度。
临床背景
This comparison occurs when selecting between SGLT2 inhibitors and DPP-4 inhibitors for type 2 diabetes treatment.
结论
Canagliflozin and Linagliptin are complementary options for type 2 diabetes with unique benefits and risks rather than one being superior.
全部药物对比